Is oral cefalexin (Keflex) safe and appropriate as first‑line treatment for a hidradenitis suppurativa flare in a pregnant patient, and what dosing regimen should be used?

Oral Cephalexin (Keflex) for HS Flare in Pregnancy

Yes, oral cephalexin is safe and appropriate as first-line systemic antibiotic therapy for hidradenitis suppurativa flares during pregnancy, with moderate-quality evidence supporting its safety and no reported adverse fetal effects. 1

Safety Profile in Pregnancy

The 2025 North American Clinical Practice Guidelines for HS in special populations provide a conditional recommendation with moderate-quality evidence that cephalexin can be used in pregnant patients with HS requiring systemic antibiotics 1. The evidence base comes from non-HS pregnant populations showing no congenital anomalies or preterm delivery risks 1.

Key safety considerations:

• FDA Pregnancy Category B: Animal reproduction studies at 0.6-1.5 times maximum human dose showed no fetal harm 2
• No teratogenic effects documented in human pregnancy studies
• Substantially excreted by kidney, requiring attention to renal function 2

Recommended Dosing Regimen

While the guidelines don't specify exact dosing for pregnant HS patients, standard approaches include:

Standard dosing: 500 mg orally 2-4 times daily

• Research demonstrates equal efficacy between twice-daily and four-times-daily regimens for skin infections 3
• Twice-daily dosing may improve adherence without compromising effectiveness
• Total daily dose remains the same regardless of frequency

Duration: Minimum 12 weeks for HS, similar to tetracycline protocols in non-pregnant patients 4

Clinical Decision Algorithm

For mild-to-moderate HS flares in pregnancy:

1. Start cephalexin 500 mg twice daily (or four times daily if preferred)
2. Continue for at least 12 weeks
3. Monitor for treatment response using pain scores and inflammatory lesion counts
4. Consider treatment breaks to assess ongoing need and limit antimicrobial resistance

For severe HS in pregnancy:

• If cephalexin fails, escalate to rifampin 300 mg + clindamycin 300 mg, both twice daily for 10-12 weeks 1
• This combination has conditional recommendation despite rifampin's historical Category C status, as CDC/WHO endorse rifampin for tuberculosis in pregnancy 1

Alternative first-line options with similar safety:

• Azithromycin (moderate evidence) 1
• Clindamycin monotherapy (moderate evidence, though less robust than combination) 1

Important Caveats

Drug interactions to monitor:

• Cephalexin increases metformin levels by 34% (Cmax) and 24% (AUC), decreasing renal clearance by 14% 2
• If patient has gestational diabetes on metformin, careful monitoring and metformin dose adjustment required
• Probenecid inhibits cephalexin renal excretion 2

Antibiotics to avoid in pregnancy:

• Doxycycline and tetracyclines (standard HS therapy in non-pregnant patients)
• Trimethoprim-sulfamethoxazole (increased risks)
• Metronidazole (risk of low birthweight, neurodevelopmental concerns) 1
• Erythromycin, dapsone 1

Monitoring requirements:

• Gastrointestinal symptoms (cephalosporins may cause C. difficile colitis) 2
• Renal function, particularly in elderly or those with baseline impairment 2
• Prothrombin time if prolonged therapy or poor nutritional state 2

Postpartum Considerations

Cephalexin is excreted in breast milk (peak 4 μg/mL at 4 hours, disappears by 8 hours) but is considered safe during breastfeeding 2. The guidelines support continuing systemic antibiotics postpartum when needed, as >50% of women experience post-partum HS flares 5, 6.

Strength of Evidence

The recommendation strength is conditional rather than strong because direct evidence in pregnant HS patients is lacking—safety data extrapolates from other pregnancy conditions 1. However, the moderate quality of safety evidence combined with established efficacy in skin infections makes cephalexin a rational first-line choice when systemic therapy is needed.